Ms Preetha Reddy (Executive Vice Chairman AHEL), Dr Prathap Reddy (Chairman AHEL), Olivier Legrain (CEO IBA) & Dr Rakesh Jalali (Clinical Director APCC)

August 19, 2022 —  IBA (Ion Beam Applications S.A., EURONEXT), a world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancerannounces it has signed a collaboration agreement with Apollo Hospitals Enterprise Ltd (AHEL), to provide proton therapy training and education programs for IBA customers in Asia. 

AEHL is a long-term customer of IBA, purchasing a ProteusPLUS[1] proton therapy system in 2013 and successfully utilizing it in the treatment of cancer patients for more than three years. Since AHEL started its proton therapy operations at Apollo Proton Cancer Centres (APCC), it has gained significant expertise and experience in treating a wide range of tumor types IBA plans to leverage this experience, working with AEHL to provide a training and education program initiative, to aspiring proton therapy users in Asia and other parts of the world. 

Olivier Legrain, Chief Executive Officer at IBA, said: "Over recent years, Apollo Hospitals has shown its expertise and enthusiasm by successfully organizing training symposia for the local and international proton therapy experts’ community. We look forward to collaborating with Apollo in order to provide high-quality training and education to our customers and prospects in Asia without them traveling to another continent." 

Dr. Prathap C Reddy, Founder and Chairman of Apollo Hospitals Enterprise Ltd, said: "An acute need for high-quality cancer care, coupled with an increasing prevalence of cancer cases in India, led to the creation of Apollo Cancer Centres (ACC) around three decades ago. Since then, ACC has continually introduced the finest and most advanced cancer care into India, with the most recent being bringing Proton Therapy to the region. Furthermore, in keeping with its resolute mission to raise the bar in cancer care for all in need, in association with IBA, the Apollo Proton Cancer Centre will be the first of its kind training and education program reference centre in Asia. 

For more information: www.iba-worldwide.com 

[1] ProteusPLUS is the brand name of IBA Proteus235. 


Related Content

News | Radiopharmaceuticals and Tracers

April 5, 2024 — RLS Radiopharmacies, America’s only Joint Commission-accredited radiopharmacy network, today announced ...

Time April 05, 2024
arrow
News | Molecular Imaging

March 29, 2024 — Magnetic resonance imaging (MRI) is a cornerstone in the landscape of medical diagnostics, celebrated ...

Time March 29, 2024
arrow
Feature | Radiation Oncology | By Christine Book

Appreciating the considerable advances in the clinical application of artificial intelligence (AI) within healthcare ...

Time March 06, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 21, 2024 — Blue Earth Therapeutics, a Bracco company and emerging leader in the development of innovative next ...

Time February 21, 2024
arrow
News | Radiopharmaceuticals and Tracers

February 14, 2024 — PanTera, the Belgian joint venture created by IBA and SCK CEN to secure large-scale production of ...

Time February 14, 2024
arrow
News | Quality Assurance (QA)

February 12, 2024 — IBA, a world leader in particle accelerator technology and a world-leading provider of dosimetry and ...

Time February 12, 2024
arrow
News | PET Imaging

February 9, 2024 — A novel PET imaging technique can noninvasively detect active inflammation in the body before ...

Time February 09, 2024
arrow
Videos | RSNA

At RSNA23, Imaging Technology News (ITN) spoke with Bhvita Jani, principal analyst at Signify Research, about ...

Time February 07, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
Subscribe Now